{"title":"重度视神经炎后水通道蛋白4免疫球蛋白g阳性、髓鞘少突胶质细胞糖蛋白免疫球蛋白g阳性和双血清阴性视神经炎患者视力结局的比较","authors":"Rawipreeya Laosirirat, Metha Apiwattanakul, Saharat Aungsumart","doi":"10.1016/j.nerep.2025.100260","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Data regarding idiopathic autoimmune-mediated optic neuritis is limited to visual acuity at specific time points post-treatment, lacking longitudinal comparisons. This study compared visual outcomes in patients with severe visual impairment due to optic neuritis who were aquaporin-4 (AQP4) immunoglobulin G (IgG)-positive, myelin oligodendrocyte glycoprotein (MOG)-IgG-positive, or double seronegative.</div></div><div><h3>Methods</h3><div>This retrospective longitudinal study was conducted at the Neurological Institute of Thailand, examining visual outcomes among three patient groups presenting with severe visual impairment—defined as best corrected visual acuity (BCVA) of 20/200 or worse—between June 2020 and May 2023. Visual outcomes were assessed with the “time to good visual recovery”—defined as ≥66.77 % improvement in BCVA from post-attack to baseline—and “complete visual recovery”—defined as BCVA returning to baseline.</div></div><div><h3>Results</h3><div>This study included 45 affected eyes of 30 patients, grouped as AQP4-IgG-positive (<em>n</em> = 10), MOG-IgG-positive (<em>n</em> = 5), and double seronegative (<em>n</em> = 30). Median BCVA at onset was 1.7 (logMAR). Using MOG-IgG as a comparator, the hazard ratios for complete visual recovery in the AQP4-IgG-positive and double seronegative groups were 0.158 (<em>p</em> = 0.135) and 0.421 (<em>p</em> = 0.288), respectively. For good visual recovery, the AQP4-IgG-positive and double seronegative subtypes had hazard ratios of 0.187 (<em>p</em> = 0.013) and 0.189 (<em>p</em> = 0.005), respectively, compared with the MOG-IgG-positive subtype. Furthermore, all MOG-IgG-positive cases achieved good visual recovery, in contrast to fewer than 50 % of the AQP4-IgG-positive and double seronegative subtypes.</div></div><div><h3>Conclusion</h3><div>The MOG-IgG-positive subtype exhibited the best visual prognosis and the shortest recovery time compared to the AQP4-IgG-positive and double seronegative subtypes.</div></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"7 ","pages":"Article 100260"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of visual outcomes in patients with aquaporin 4 immunoglobulin g-positive, myelin oligodendrocyte glycoprotein immunoglobulin g-positive, and double seronegative optic neuritis following severe optic neuritis\",\"authors\":\"Rawipreeya Laosirirat, Metha Apiwattanakul, Saharat Aungsumart\",\"doi\":\"10.1016/j.nerep.2025.100260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Data regarding idiopathic autoimmune-mediated optic neuritis is limited to visual acuity at specific time points post-treatment, lacking longitudinal comparisons. This study compared visual outcomes in patients with severe visual impairment due to optic neuritis who were aquaporin-4 (AQP4) immunoglobulin G (IgG)-positive, myelin oligodendrocyte glycoprotein (MOG)-IgG-positive, or double seronegative.</div></div><div><h3>Methods</h3><div>This retrospective longitudinal study was conducted at the Neurological Institute of Thailand, examining visual outcomes among three patient groups presenting with severe visual impairment—defined as best corrected visual acuity (BCVA) of 20/200 or worse—between June 2020 and May 2023. Visual outcomes were assessed with the “time to good visual recovery”—defined as ≥66.77 % improvement in BCVA from post-attack to baseline—and “complete visual recovery”—defined as BCVA returning to baseline.</div></div><div><h3>Results</h3><div>This study included 45 affected eyes of 30 patients, grouped as AQP4-IgG-positive (<em>n</em> = 10), MOG-IgG-positive (<em>n</em> = 5), and double seronegative (<em>n</em> = 30). Median BCVA at onset was 1.7 (logMAR). Using MOG-IgG as a comparator, the hazard ratios for complete visual recovery in the AQP4-IgG-positive and double seronegative groups were 0.158 (<em>p</em> = 0.135) and 0.421 (<em>p</em> = 0.288), respectively. For good visual recovery, the AQP4-IgG-positive and double seronegative subtypes had hazard ratios of 0.187 (<em>p</em> = 0.013) and 0.189 (<em>p</em> = 0.005), respectively, compared with the MOG-IgG-positive subtype. Furthermore, all MOG-IgG-positive cases achieved good visual recovery, in contrast to fewer than 50 % of the AQP4-IgG-positive and double seronegative subtypes.</div></div><div><h3>Conclusion</h3><div>The MOG-IgG-positive subtype exhibited the best visual prognosis and the shortest recovery time compared to the AQP4-IgG-positive and double seronegative subtypes.</div></div>\",\"PeriodicalId\":100950,\"journal\":{\"name\":\"Neuroimmunology Reports\",\"volume\":\"7 \",\"pages\":\"Article 100260\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimmunology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667257X25000142\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X25000142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparison of visual outcomes in patients with aquaporin 4 immunoglobulin g-positive, myelin oligodendrocyte glycoprotein immunoglobulin g-positive, and double seronegative optic neuritis following severe optic neuritis
Background
Data regarding idiopathic autoimmune-mediated optic neuritis is limited to visual acuity at specific time points post-treatment, lacking longitudinal comparisons. This study compared visual outcomes in patients with severe visual impairment due to optic neuritis who were aquaporin-4 (AQP4) immunoglobulin G (IgG)-positive, myelin oligodendrocyte glycoprotein (MOG)-IgG-positive, or double seronegative.
Methods
This retrospective longitudinal study was conducted at the Neurological Institute of Thailand, examining visual outcomes among three patient groups presenting with severe visual impairment—defined as best corrected visual acuity (BCVA) of 20/200 or worse—between June 2020 and May 2023. Visual outcomes were assessed with the “time to good visual recovery”—defined as ≥66.77 % improvement in BCVA from post-attack to baseline—and “complete visual recovery”—defined as BCVA returning to baseline.
Results
This study included 45 affected eyes of 30 patients, grouped as AQP4-IgG-positive (n = 10), MOG-IgG-positive (n = 5), and double seronegative (n = 30). Median BCVA at onset was 1.7 (logMAR). Using MOG-IgG as a comparator, the hazard ratios for complete visual recovery in the AQP4-IgG-positive and double seronegative groups were 0.158 (p = 0.135) and 0.421 (p = 0.288), respectively. For good visual recovery, the AQP4-IgG-positive and double seronegative subtypes had hazard ratios of 0.187 (p = 0.013) and 0.189 (p = 0.005), respectively, compared with the MOG-IgG-positive subtype. Furthermore, all MOG-IgG-positive cases achieved good visual recovery, in contrast to fewer than 50 % of the AQP4-IgG-positive and double seronegative subtypes.
Conclusion
The MOG-IgG-positive subtype exhibited the best visual prognosis and the shortest recovery time compared to the AQP4-IgG-positive and double seronegative subtypes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
